Bushen Kayxuan Tongluo formulasi CAMP/PKA/CREB-Bcl-2 yo‘lini faollashtirish va glyukoza-lipid metabolizmini yaxshilash orqali Db/db sichqonlarda diabetik buyrak kasalligini yaxshilaydi.
Oct 15, 2025
3 Natijalar
3.1 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining umumiy sharoitlariga ta'siri
Bo'sh guruhdagi sichqonlar porloq mo'yna bilan faol edi. Model guruhidagi sichqonlar semirib ketgan, beparvo bo'lgan va faollik vaqtini sezilarli darajada qisqartirgan. Barcha dori guruhlaridagi sichqonlar model guruhiga nisbatan ma'lum yaxshilanishlarni ko'rsatdi.

BUYRAK SOG'LIGI UCHUN TCM O'TI CISTANCHE EKSTRAKTI
3.2 Bushen Kaixuan Tongluo formulasining db/db sichqonlarning tana vazniga ta'siri
Eksperimental davrda, bo'sh guruh bilan solishtirganda, model guruhidagi tana vazni sezilarli darajada oshdi (P<0.01). Compared with the model group, body weight in all medication groups tended to decrease, with differences appearing from week 8; the high-dose Bushen Kaixuan Tongluo Formula group showed the best effect. See Table 2.
2-jadval. Cistanche-asoslangan formulaning JB/db sichqonlarda tana vazniga ta'siri (x̄±s, n=6)
| Guruh | Doza (g·kg⁻¹) | 0-hafta (g) | 4-hafta (g) | 8-hafta (g) | 12-hafta (g) |
|---|---|---|---|---|---|
| Bo'sh | - | 24.38 ± 0.35 | 29.88 ± 0.46 | 32.92 ± 0.90 | 33.14 ± 0.49 |
| Model | - | 37.27 ± 1.46 | 45.63 ± 1.85¹ | 49.38 ± 3.52² | 50.86 ± 4.69² |
| Kam dozali formula | 7 | 36.47 ± 1.40 | 44.07 ± 1.84 | 43.41 ± 3.11 | 40.03 ± 1.36³ |
| O'rta dozali formula | 14 | 37.57 ± 1.01 | 44.23 ± 2.05 | 42.47 ± 3.36³ | 40.25 ± 4.78³ |
| Yuqori dozali formula | 28 | 38.03 ± 1.62 | 43.28 ± 1.63 | 40.82 ± 1.87⁴ | 36.49 ± 1.32⁴ |
| Irbesartan | 0.02 | 38.58 ± 1.66 | 44.63 ± 1.66 | 46.03 ± 2.10 | 44.83 ± 2.43 |
3.3 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining buyrak funktsiyasiga ta'siri
Bo'sh guruh bilan taqqoslaganda, model guruhidagi Scr statistik ahamiyatga ega bo'lmagan holda o'sish tendentsiyasini ko'rsatdi, BUN, uALB va ACR darajalari esa sezilarli darajada ko'tarildi (P).<0.05). Compared with the model group, Scr in the formula groups tended to decrease without statistical significance; BUN, uALB, and ACR were significantly reduced (P<0.05), with the medium-dose formula group showing the best effect. In the irbesartan group, Scr and BUN tended to decrease without statistical significance, while uALB and ACR decreased significantly (P<0.01). See Table 3.
3-jadval. Sistanxga asoslangan formulaning db/db sichqonlarda buyrak funktsiyasiga ta'siri (x̄±s, n=6)
| Guruh | Doza (g·kg⁻¹) | Scr (mkmol/L) | BUN (mmol/L) | uALB (mg/L) | ACR (mg/g) |
|---|---|---|---|---|---|
| Bo'sh | - | 53.76 ± 0.91 | 6.79 ± 0.26 | 1.69 ± 0.13 | 9.54 ± 1.01 |
| Model | - | 61.34 ± 1.89 | 9.08 ± 0.73¹ | 4.16 ± 0.19² | 63.08 ± 9.92² |
| Kam dozali formula | 7 | 55.69 ± 3.55 | 6.99 ± 0.54³ | 1.81 ± 0.05⁴ | 21.37 ± 0.62⁴ |
| O'rta dozali formula | 14 | 50.45 ± 3.02 | 6.48 ± 0.26⁴ | 1.21 ± 0.08⁴ | 19.99 ± 2.03⁴ |
| Yuqori dozali formula | 28 | 51.59 ± 3.09 | 6.01 ± 0.30⁴ | 1.34 ± 0.09⁴ | 22.72 ± 1.38⁴ |
| Irbesartan | 0.02 | 55.33 ± 2.31 | 7.93 ± 0.48 | 1.37 ± 0.09⁴ | 27.00 ± 3.83⁴ |
3.4 Bushen Kaixuan Tongluo formulasining jigar funktsiyasi va db / db sichqonlarining lipid metabolizmiga ta'siri
Bo'sh guruh bilan taqqoslaganda, model guruhidagi ALT, AST, TC va TG darajalari sezilarli darajada oshdi (P).<0.05). Compared with the model group, AST and ALT in the formula groups showed downward trends without statistical significance, TC decreased significantly (P<0.01), TG in the medium-dose formula group decreased significantly (P<0.05), and other TCM groups showed a downward trend in TG without statistical significance. In the irbesartan group, TC showed a downward trend without statistical significance, while TG decreased significantly (P<0.01). See Table 4.

Jadval 4. Sistanxga asoslangan formulaning jigar faoliyati va lipid metabolizmiga ta'siri (x̄±s, n=6)
| Guruh | Doza (g·kg⁻¹) | AST (U/L) | ALT (U/L) | TC (mmol/L) | TG (mmol/l) |
|---|---|---|---|---|---|
| Bo'sh | - | 158.80 ± 6.44 | 56.31 ± 3.00 | 2.40 ± 0.08 | 1.22 ± 0.11 |
| Model | - | 310.20 ± 53.31¹ | 206.70 ± 24.98² | 2.98 ± 0.21¹ | 3.71 ± 0.22² |
| Kam dozali formula | 7 | 202.50 ± 22.27 | 125.30 ± 8.74 | 2.09 ± 0.06⁴ | 3.13 ± 0.18 |
| O'rta dozali formula | 14 | 263.10 ± 31.37 | 166.80 ± 34.28 | 1.94 ± 0.10⁴ | 2.23 ± 0.32⁴ |
| Yuqori dozali formula | 28 | 266.20 ± 22.96 | 166.80 ± 22.61 | 1.97 ± 0.05⁴ | 2.96 ± 0.26 |
| Irbesartan | 0.02 | 215.30 ± 14.43 | 101.70 ± 20.41² | 2.50 ± 0.19 | 2.42 ± 0.31⁴ |
3.5 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining glyukoza metabolizmiga ta'siri
Bo'sh guruh bilan taqqoslaganda, model guruhida FBG, LEP, GSP va INS darajalari sezilarli darajada oshdi (P).<0.05). Compared with the model group, FBG in the medication groups showed no downward trend; LEP in the formula groups tended to decrease without statistical significance, while LEP in the irbesartan group decreased significantly (P<0.05). GSP and INS decreased significantly in all medication groups (P<0.05), with the high-dose formula group showing the best effect. See Table 5.
Jadval 5. Sistanxga asoslangan formulaning db/db sichqonlarda glyukoza metabolizmiga ta'siri (x̄±s, n=6)
| Guruh | Doza (g·kg⁻¹) | FBG (mmol/l) | LEP (ng/ml) | GSP (mkmol/l) | INS (mIU/ml) |
|---|---|---|---|---|---|
| Bo'sh | - | 4.17 ± 0.26 | 5.32 ± 0.18 | 127.30 ± 2.69 | 7.99 ± 0.13 |
| Model | - | 18.87 ± 3.84² | 6.46 ± 0.22¹ | 239.40 ± 14.98² | 23.34 ± 2.16² |
| Kam dozali formula | 7 | 28.22 ± 2.30 | 5.60 ± 0.30 | 201.80 ± 4.68⁴ | 18.52 ± 0.72³ |
| O'rta dozali formula | 14 | 28.00 ± 3.33 | 5.98 ± 0.46 | 193.30 ± 5.79⁴ | 15.64 ± 0.33⁴ |
| Yuqori dozali formula | 28 | 33.30 ± 0.00⁴ | 5.50 ± 0.08 | 178.70 ± 2.63⁴ | 14.57 ± 0.23⁴ |
| Irbesartan | 0.02 | 25.62 ± 2.36 | 5.27 ± 0.14³ | 163.80 ± 2.32⁴ | 14.28 ± 0.57⁴ |
3.6 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining buyrak gistopatologiyasiga ta'siri
HE binoni bo'sh guruhda normal buyrak tuzilishini ko'rsatdi: muntazam glomeruli va buzilmagan quvurli epiteliya hujayralari. Model guruhi tartibsiz glomerulyar morfologiyani, o'rtacha mezangial hujayra proliferatsiyasini, yallig'lanish hujayralari infiltratsiyasini va quvurli epiteliya hujayralarining vakuolyar degeneratsiyasini namoyish etdi. Ushbu patologik o'zgarishlar past, o'rta va yuqori dozali formulali guruhlarda va irbesartan guruhida turli darajada engillashtirildi. (Rasm matn xulosasiga aylantirildi.)
PAS bo'yalishi bo'sh guruhning glomeruliyalarida hujayradan tashqari matritsaning (ECM) oz miqdorini ko'rsatdi, model guruhi esa massiv ECM cho'kmasini va sezilarli darajada qalinlashgan bazal membranalarni ko'rsatdi. Ushbu patologik xususiyatlar formulaning barcha uchta doza guruhida va irbesartan guruhida ma'lum darajada yaxshilandi. (Rasm matn xulosasiga aylantirildi.)
Masson binoni bo'sh guruhda minimal patologik kollagen cho'kmasi bilan normal glomerulyar tuzilmani ko'rsatdi. Model guruhi glomeruli va interstitiumda keng ko'k kollagen tolasi cho'kmasini ko'rsatdi. Formuladagi doza guruhlari va irbesartan guruhi turli darajadagi yaxshilanishlarni ko'rsatdi. (Rasm matn xulosasiga aylantirildi.)
3.7 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining buyrak to'qimalarida p-PKA va p-CREB ifodasiga ta'siri
Bo'sh guruh bilan taqqoslaganda, model guruhining buyrak to'qimalarida p-PKA va p-CREB ning bo'yash intensivligi sezilarli darajada kamaydi (P).<0.01). Compared with the model group, p-PKA expression in the medium-dose formula group increased significantly (P<0.01), and p-CREB showed an upward trend without statistical significance. See Figure 4 and Table 6. (Image converted to text summary.)

3.8 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining buyrak to'qimalarida p-PKA, PKA, p-CREB, CREB va Bcl-2 ning protein ifodasiga ta'siri
Bo'sh guruh bilan taqqoslaganda, model guruhida p-PKA / PKA va p-CREB / CREB, shuningdek, Bcl-2 darajalari protein ifoda nisbatlari sezilarli darajada kamaydi (P).<0.05). Compared with the model group, these indices were significantly increased in the medium-dose formula group (P<0.01). See Figure 5 and Table 7. (Image converted to text summary.)
3.9 Bushen Kaixuan Tongluo formulasining db/db sichqonlarining buyrak to'qimalarida PKA, CREB va Bcl-2 ning mRNK ifodasiga ta'siri.
Bo'sh guruh bilan solishtirganda, model guruhida PKA, CREB va Bcl-2 ning mRNK ifodasi sezilarli darajada kamaydi (P).<0.01). Compared with the model group, mRNA expression of PKA, CREB, and Bcl-2 was significantly increased in the medium-dose formula group (P<0.05). See Table 8.
Mexanik kontekst va muhokamadan parcha
cAMP signalizatsiyasi energiya almashinuvi va genlarni tartibga solish uchun markaziy markaz bo'lib, buyrak gomeostazi uchun juda muhimdir. Adenilat siklaza (AC) PKA ni allosterik ravishda faollashtiradigan cAMP hosil qiladi. Faollashtirilgan PKA p-CREBni hosil qilish uchun CREBni fosforlaydi, u yadroga o'tadi, maqsadli promotorlarda cAMP javob elementlarini (CRE) bog'laydi va anti-apoptotik ta'sir ko'rsatish va hujayra shikastlanishini yumshatish uchun Bcl-2 kabi quyi oqim effektorlarining transkripsiyasini boshlaydi.
DKDda surunkali giperglikemiya AC faolligini bostiradi va fosfodiesteraza (PDE) degradatsiyasini kuchaytiradi, cAMP darajasini pasaytiradi, PKA / CREB signalini zaiflashtiradi, mitoxondriyal funktsiyani, antioksidant sintezni va anti-apoptotik omil ifodasini buzadi, shu bilan glomeruloz va tuberulozni tezlashtiradi.
cAMP/PKA signalizatsiyasini faollashtirish podotsitlar diafragma oqsillarini saqlashga yordam beradi, filtratsiya to'sig'ini himoya qiladi, proteinuriyani kamaytiradi, antioksidant genlarni (masalan, SOD2) qo'zg'atadi va ROS to'planishini oldini olish va yuqori glyukoza sharoitida hujayralarni himoya qilish uchun Bcl-2 ni oshiradi.
Qon glyukozasini normallashtirish va lipid profilini yaxshilash AGE to'planishini kamaytirishi, GBM qalinlashishi va podotsitlar shikastlanishini kamaytirishi va buyrak lipidlari va makrofaglarning infiltratsiyasini bostirishi mumkin, natijada skleroz va fibrozni kechiktiradi.
Ushbu tadqiqotda formula umumiy holatni yaxshiladi, buyrak funktsiyasini sezilarli darajada yaxshiladi va db / db sichqonlarida glyukoza-lipid almashinuvi buzilishlarini tuzatdi. Gistopatologiyada GBM qalinlashuvi, mezangial kengayish va interstitsial kollagen cho'kishining yengilligi ko'rsatilgan. Mexanik jihatdan formula buyrak PKA, CREB va Bcl-2 mRNK ni ko'tardi va p-PKA/PKA, p-CREB/CREB va Bcl-2 protein darajasini oshirdi, cAMP yo'lining asosiy tugunlarini faollashtirdi, antioksidant qobiliyatini oshirdi va filtrlash to'siqni funktsiyasini yaxshilaydi.
Xulosa: Bushen Kaixuan Tongluo formulasi jigar va buyraklar faoliyatini yaxshilaydi, lipid va glyukoza almashinuvi buzilishlarini tuzatadi, cAMP yo'lini ko'tarish orqali buyrak fibrozi va oksidlovchi stressni susaytiradi va shu bilan renoproteksiyani ta'minlaydi. Ko'p darajali dalillar cAMP yo'lining ishtirokini qo'llab-quvvatlasa-da, BDNF kabi quyi oqim effektorlari tekshirilmagan va kelajakda tekshirishni kafolatlaydi.
Manfaatlar to'qnashuvi
Manfaatlar to'qnashuvi yo'q.
Ma'lumotnomalar
[1] Yang R, Chen R, Xu N va boshqalar. DKDda buyrak shikastlanishini yumshatish uchun PRSS3 ning terapevtik maqsadi. Cell Biol Toxicol. 2025;41(1):108.
[2] Vang Y, Gu S, Xie Z va boshqalar. 1990 yildan 2021 yilgacha Xitoyda 2-toifa diabet tufayli surunkali buyrak kasalligi yukining tendentsiyalari va nomutanosibliklari: Aholi asosidagi tadqiqot. J Qandli diabet. 2025;17(4):e70084.
[3] língí, líííí, líííí, lííí, yí. PI3K/Aktzīngīngīngīngīngīngīngīngīngīngīngjīngīngīngīngīngīng. chàngàngàngàngàngìnìnì. 2025;31(11):90-97. Ingliz tilidagi iqtibos: Xu M, Jia XL, Qin LL va boshqalar. Diabetik nefropatiyaning oldini olish va davolashda PI3K / Akt signalizatsiya yo'li bo'yicha tadqiqotlar va an'anaviy xitoy tibbiyotining aralashuvi. Chin J Exp Tradit Med shakli. 2025;31(11):90-97.
[4] língín, língíní, língíní, língín, lín. nrf2shíngíngíngíngíngíngíngíngíngíngíngíníngíngíníngíníngín. chàngàngǎngǎngǎngyàn. 2025;31(18):277-285. Ingliz tilidagi iqtibos: Chjan QY, Chen YX, Qin DK va boshqalar. Nrf2 signalizatsiya yo'lini tartibga solish orqali diabetik nefropatiyaga an'anaviy xitoy tibbiyotining aralashuvi: ko'rib chiqish. Chin J Exp Tradit Med shakli. 2025;31(18):277-285.
[5] Chjan Y, Yang Y, Xu X va boshqalar. RAS oqsiliga o'xshash faollashtiruvchi 2 (RASAL2) gipoksik buyrak interstitsial fibrozida peritubulyar kapillyar kamayishni boshlaydi. Transl Res. 2024;269:14-30.
[6] Vang H, Shi H, Sheng G va boshqalar. Yucan formulasining kimyoviy-farmakologik uzluksizligi: Integratsiyalashgan komponent-to'qimalarga ta'sir qilish korrelyatsiyasi diabetik buyrak kasalligi maqsadli tarmog'ini xabardor qiladi. J Chromatogr B Analyt Technol Biomed Life Sci. 2025:124715.
[7] līngī, līngīī, ičiči. "língjíngín"língíngíngíngíngíngíngíníngíníngíngín. língínzhí. 2022;53(04):12-15. Ingliz tilidan iqtibos: Vang T, Huang LJ, Yu JY. Diabetik nefropatiyaning oldini olish va davolash strategiyasi "Kasalliklarni profilaktika davolash" rahbarligi ostida. Jiangxi J Tradit Chin Med. 2022;53(04):12-15.
[8] 周洛卿, 王友, 贾晓蕾, 等. 补肾开玄通络方联合西药治疗G3a期糖尿病肾病的疗效观察. 北京中医药. 2024;43(05):551-554.






